静脉注射靶向囊泡包封的茶多酚表没食子儿茶素没食子酸酯的抗肿瘤活性。
Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration.
机构信息
Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
出版信息
Nanomedicine (Lond). 2013 Feb;8(2):181-92. doi: 10.2217/nnm.12.83. Epub 2012 Aug 14.
AIM
The therapeutic potential of epigallocatechin-3-gallate (EGCG), a green tea polyphenol with anticancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study was to determine whether a tumor-targeted vesicular formulation of EGCG would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.
MATERIALS & METHODS: Transferrin-bearing vesicles encapsulating EGCG were administered intravenously to mice bearing subcutaneous A431 and B16-F10 tumors.
RESULTS
The intravenous administration of EGCG encapsulated in transferrin-bearing vesicles resulted in tumor suppression in 40% of A431 and B16-F10 tumors. Animal survival was improved by more than 20 days compared with controls.
CONCLUSION
Encapsulation of EGCG in transferrin-bearing vesicles is a promising therapeutic strategy.
目的
表没食子儿茶素没食子酸酯（EGCG）是一种具有抗癌特性的绿茶多酚，其治疗潜力受到限制，因为它在静脉给药后无法专门到达肿瘤。本研究旨在确定 EGCG 的肿瘤靶向囊泡制剂是否会抑制体外和体内 A431 表皮样癌细胞和 B16-F10 黑色素瘤的生长。
材料与方法
将携带转铁蛋白的囊泡包裹的 EGCG 静脉给药给患有皮下 A431 和 B16-F10 肿瘤的小鼠。
结果
静脉给予转铁蛋白囊泡包裹的 EGCG 导致 40%的 A431 和 B16-F10 肿瘤受到抑制。与对照组相比，动物的存活时间延长了 20 多天。
结论
将 EGCG 包裹在转铁蛋白囊泡中是一种很有前途的治疗策略。
Zotero 插件